Navigation Links
New leukemia signal could point way to better treatment, Stanford researchers find
Date:9/17/2008

micals that inhibit various cell signals. When a GSK3 inhibitor clobbered cells with mutant MLL genes, Wang realized his work was cut out for him.

"I was excited, but I knew I'd have to do lots of work to confirm the finding," he said. "Most people say GSK3 cannot be a cancer target." That's because of earlier discoveries that showed GSK3 slowed malignancies such as colon cancer.

But Wang's extensive follow-up experiments confirmed GSK3 drove leukemia. For instance, he gave the psychiatric drug lithium, a weak GSK3 inhibitor, to mice with MLL-gene leukemia. Mice that got lithium lived longer than those that did not.

Now that the team knows GSK3 is a potential anti-leukemia target, they're studying how the signal revs up cancer.

They're also starting the hunt for high-potency GSK3 inhibitors that could safely be given to humans. The signal is an especially promising leukemia drug target, the researchers said, because GSK3 normally slows the growth of healthy bone marrow stem cells. Thus, it's possible that giving GSK3 inhibitors will have a double-whammy effect on leukemia, killing the cancerous white blood cells and promoting growth of healthy stem cells, such as those given in a bone marrow transplant.

"Most current cancer drugs target both the normal and the aberrant cells," Cleary said. It would be a big advantage in cancer treatment if a drug were developed that could selectively kill cancer but help healthy cells grow. Of course, the danger with GSK3 inhibitors would be that they might also cause other cancers if given long-term. Cleary said it's too early to tell if or how a new drug might skirt that problem.

"There will be a lot of hard work required to get better anti-GSK3 compounds, test them in preclinical models and translate them to human trials," he said.


'/>"/>

Contact: Erin Digitale
digitale@stanford.edu
650-724-9175
Stanford University Medical Center
Source:Eurekalert

Page: 1 2

Related medicine news :

1. The Leukemia & Lymphoma Society: Standing Up to Cancer for 60 Years
2. Stater Bros. Raises $200,000 for the Leukemia & Lymphoma Society
3. Methadone Kills Resistant Leukemia Cells
4. FDA Accepts Gentas NDA Amendment as Complete Response for Genasense(R) Treatment of Chronic Lymphocytic Leukemia
5. Leukemia drug could save lives of stroke patients
6. Math could help cure leukemia
7. Gene mutation improves leukemia drugs effect
8. Microenvironment a main driver of aggressive multi-lineage leukemia disease type
9. Clinical study shows biological and clinical activity in relapsed leukemia patients
10. Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting
11. UCLA researchers identify leukemia stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... South Florida’s leading urgent care provider, MD ... daze of hassle, hustle, and bustle that can cause injuries ... burns when making special meals and heartburn after eating them, ... any time. To prevent this season of joy from becoming ... of helpful and healthful holiday tips to keep the season ...
(Date:12/15/2014)... Beltsville, MD (PRWEB) December 15, 2014 ... and services today released “ Social Media Cheat Sheets ... cultivating a community that drives results on the top ... a marketing program. It helps drive awareness, engagement, and ... conversions. For marketers to make an impact on new ...
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
Breaking Medicine News(10 mins):Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4
... , Anti-Abortion Extremist Ejected After "Murder" ... night in northern Virginia, Representative James Moran and Governor Howard Dean ... by thousands of people. Anti-abortion extremist Randall Terry, the founder of ... be there to disrupt it by accusing President Obama of "killing ...
... million acres in the southeastern United States, may sprout into ... the first evidence that root extracts from kudzu show promise ... metabolic syndrome that affects almost 50 million people in ... issue of ACS, Journal of Agricultural and Food Chemistry ...
... BATESVILLE, Ind., Aug. 26 Hill-Rom Holdings, Inc., (NYSE: HRC ) ... CEO, Hill-Rom, at the Thomas Weisel Partners Healthcare Conference in Boston on Thursday, ... , You are invited to listen to the live discussion via ... or access it directly at http://www.ver a ...
... , , , ... PRA International, a leading Clinical Research Organization, will host ... region in global clinical research studies. In this audio conference, ... discuss the benefits and challenges of managing clinical trials in ...
... , MORRIS PLAINS, N.J., Aug. 26 New entries ... care of their eyes. , , "Eye ... of several factors including indoor and outdoor irritants and allergens like dust, ... process," says Elise Brisco, O.D. "Since many people experience more ...
... , , , ... PPHM ) today announced that the U.S. National ... two-year, $763,000 grant to Philip Thorpe, Ph.D., of the University ... of anti-phosphatidylserine (anti-PS) antibodies as potential treatments for viral hemorrhagic ...
Cached Medicine News:Health News:Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 2Health News:Hill-Rom to Participate at the Thomas Weisel Partners 2009 Healthcare Conference 2Health News:PRA International to Host Audio Conference 2Health News:Breakthroughs in Eye Care Products Offer Fresh Approach for Soothing Eyes 2Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 2Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 3Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 4Health News:NIAID Awards New Grant to Expand Studies of Peregrine's Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers 5
(Date:12/17/2014)... 17, 2014  Beamz Interactive, Inc. (OTCQB: BZIC), ... today announced that it has signed an agreement ... supplier of innovative prosthetic, orthotic and assistive technology ... the agreement, RSL Steeper will promote and supply ... for use within UK residential care facilities through ...
(Date:12/17/2014)... 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... developing and commercializing innovative therapies addressing major unmet ... enrollment in its first Phase 2a study, RXI-109-1301.  ... the 1-month findings that were reported in September ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... trauma surgeon at Brooke Army Medical Center in San Antonio, ... announcement on April 28, 2011, that the U.S. Food and ... its CARDIOHELP System in the United States as a cardiac ... "The ability to bring environmental control and life ...
... Sciences, Inc., (GT) a privately held biotechnology company announced ... AND METHODS FOR CONSTRUCTING GENOMIC-BASED PHENOTYPIC MODELS" by the ... has a priority date of June 14, 2002 and ... modeling processes by which scientists may use computational models ...
Cached Medicine Technology:GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling 2GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: